Periodicidad semestral: flujo continuo.
ISSN - Electrónico: 2661-6947 / DOI: 10.36015 • LILACS BIREME (19784); LATINDEX (20666)
INTRODUCTION. Procalcitonin is a biomarker that can be used as a diagnostic support in bacterial infections and the monitoring of antibiotic treatment, especially in patients with sepsis. Hence, it was used during the COVID-19 pandemic OBJECTIVE. To determine the values of procalcitonin in patients with COVID-19 and to define a possible correlation between its increase and linkage in co-infection or secondary infection by Klebsiella pneumoniae and Pseudomonas aeruginosa with multidrug resistance and extended resistance to antibiotics. MATERIALS AND METHODS. Retrospective observational, descriptive cross-sectional study, conducted from May 1 to October 31, 2020 at the Hospital de Especialidades Carlos Andrade Marín on 7028
adult patients, hospitalized, with diagnosis of COVID-19, and procalcitonin results, whose tracheal secretion and/or blood culture samples presented development of Klebsiella pneumoniae and Pseudomonas aeruginosa. Their statistical analysis was developed using Pearson’s Chi-squared test. RESULTS. We received 861 blood culture and 391 tracheal secretion samples, obtaining: 32% isolates of Klebsiella pneumoniae and multidrug-resistant and extremely resistant Pseudomonas aeruginosa.
Among the COVID-19 patients who died, 34.4% showed increased procalcitonin levels. On the contrary, among patients who survived, only 8.8% showed increased procalcitonin levels, showing a link between increased procalcitonin levels and mortality. CONCLUSIONS. There is no difference in relation to the increase in procalcitonin values in COVID-19 patients with co-infection or secondary infection by Klebsiella
pneumoniae and multidrug-resistant and extremely resistant Pseudomonas aeruginosa and procalcitonin values in patients with co-infection and secondary infection with other types of bacterial isolates.
EFERENCIAS BIBLIOGRAFICAS
Ahmed S, Jafri L, Hoodbhoy Z, Siddiqui I. Prognostic value of serum procalcitonin in covid-19 patients: A systematic review. Indian J Crit Care Med [Internet]. 2021;25(1):77–84. Available from:
https://www.ijccm.org/doi/pdf/10.5005/jp-journals-10071-23706
Kumar A, Karn E, Trivedi K, Kumar P, Chauhan G, Kumari A, et al. Procalcitonin as a predictive marker in COVID-19: A systematic review and meta-analysis. PLoS One [Internet]. 2022;17(9 9):1–22. Available from: http://dx.doi.org/10.1371/journal.pone.0272840
Moretti M, Van Laethem J, Minini A, Pierard D, Malbrain MLNG. Ventilator-associated bacterial pneumonia in coronavirus 2019 disease, a retrospective monocentric cohort study. J Infect Chemother [Internet]. 2021;27(6):826–33. Available from:
https://doi.org/10.1016/j.jiac.2021.01.011
Martono, Fatmawati F, Mulyanti S. Risk Factors Associated with the Severity of COVID-19. Malaysian J Med Sci
[Internet]. 2023;30(3):84–92. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10325129/
Kaçmaz B, Keske Ş, Sişman U, Ateş ST, Güldan M, Beşli Y, et al. COVID-19 associated bacterial infections in intensive care unit: a case control study. Sci Rep [Internet]. 2023;13(1):1–7. DOI: https://doi.org/10.1038/s41598-023-39632-2. Available from:
https://www.nature.com/articles/s41598-023-39632-2
Scott H, Zahra A, Fernandes R, Fries BC, Thode HC, Singer AJ. Bacterial infections and death among patients with Covid-19 versus non Covid-19 patients with pneumonia. Am J Emerg Med [Internet]. 2022;51(January):1–5. Available from:
https://pubmed.ncbi.nlm.nih.gov/34637995/
Chang R, Elhusseiny KM, Yeh YC, Sun WZ. COVID-19 ICU and mechanical ventilation patient characteristics
and outcomes—A systematic review and meta-analysis. PLoS One [Internet]. 2021;16(2 February):1–16. DOI:
http://dx.doi.org/10.1371/journal.pone.0246318. Available from:
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0246318
Paudel R, Dogra P, Montgomery-Yates AA, Yataco AC. Procalcitonin: A promising tool or just another overhyped test? Int J Med Sci [Internet]. 2020;17(3):332–7. Available from:
https://medsci.org/v17p0332.pdf
Gregoriano C, Heilmann E, Molitor A, Schuetz P. Role of procalcitonin use in the management of sepsis. J Thorac Dis [Internet]. 2020;2(Suppl 1):S5–15. Available from: https://
www.ncbi.nlm.nih.gov/pmc/articles/PMC7024752/
Nag VL, Kaur N. Superinfections in COVID-19 Patients: Role of Antimicrobials. Dubai Med J [Internet].
;4(2):117–26. Available from:
https://karger.com/dmj/article-pdf/4/2/117/2624007/000515067.pdf
Azzini AM, Dorizzi RM, Sette P, Vecchi M, Coledan I, Righi E, et al. A 2020 review on the role of procalcitonin
in different clinical settings: an update conducted with the tools of the Evidence Based Laboratory Medicine. Ann Transl Med [Internet]. 2020;8(9):610–610. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290560/
Wolfisberg S, Gregoriano C, Schuetz P. Procalcitonin for individualizing antibiotic treatment: an update with
a focus on COVID-19. Crit Rev Clin Lab Sci [Internet]. 2022;59(1):54–65. DOI: https://doi.org/10.1080/1040836
2021.1975637. Available from:
https://www.tandfonline.com/doi/full/10.1080/10408363.2021.1975637
Schuetz P. How to best use procalcitonin to diagnose infections and manage antibiotic treatment. Clin Chem Lab Med [Internet]. 2023;61(5):822–8. Available from:
https://pubmed.ncbi.nlm.nih.gov/36317790/
Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect [Internet]. 2020;26(12):1622–9. DOI: https://doi.org/10.1016/j.cmi.2020.07.016. Available from:
https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(20)30423-7/fulltext
Pozo JLD. Respiratory co-and superinfections in covid-19. Rev Esp Quimioter [Internet]. 2021;34:69–71. DOI:
http://www.doi.org/10.37201/req/s01.20.2021. Available from:
https://pubmed.ncbi.nlm.nih.gov/34598432/
Montrucchio G, Corcione S, Sales G, Curtoni A, De Rosa FG, Brazzi L. Carbapenem-resistant Kleb-
siella pneumoniae in ICU-admitted COVID-19 patients: Keep an eye on the ball. J Glob Antimicrob Resist [In-
ternet]. 2020;23:398–400. DOI: https://doi.org/10.1016/j.jgar.2020.11.004. Available from:
https://www.sciencedirect.com/science/article/pii/S2213716520302927?via%-3Dihub
Westblade LF, Simon MS, Satlin MJ. Bacterial Coinfections in Coronavirus Disease 2019. Trends Micro-
biol [Internet]. 2021;29(10):930–41. DOI: https://doi.org/10.1016/j.tim.2021.03.018. Available fromo:
https://doi.org/10.1016/j.tim.2021.03.018
Al-Hadidi SH, Alhussain H, Abdel Hadi H, Johar A, Yassine HM, Al Thani AA, et al. The Spectrum of Anti-
biotic Prescribing during COVID-19 Pandemic: A Systematic Literature Review. Microb Drug Resist [Internet].
;27(12):1705–25. DOI: https://www.liebertpub.com/doi/pdf/10.1089/mdr.2020.0619. Available from:
https://www.liebertpub.com/doi/pdf/10.1089/mdr.2020.0619
Mohsen S, Dickinson JA, Somayaji R. Update on the adverse effects of antimicrobial therapies in community
practice. Can Fam Physician [Internet]. 2020;66(9):651–9. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491661/
Malcolm W, Seaton RA, Haddock G, Baxter L, Thirlwell S, Russell P, et al. Impact of the COVID-19 pandemic on
community antibiotic prescribing in Scotland. JAC-Antimicrobial Resist [Internet]. 2021;2(4):1–4. DOI: https://
doi.org/10.1093/jacamr/dlaa105. Available from:
https://academic.oup.com/jacamr/article/2/4/dlaa105/6027206
Zhang A, Hobman E V., De Barro P, Young A, Carter DJ, Byrne M. Self-medication with antibiotics for protection against COVID-19: The role of psychological distress, knowledge of, and experiences with antibiotics. Antibiotics [Internet]. 2021;10(3):1–14. Available from:
https://pubmed.ncbi.nlm.nih.gov/33668953/
Jiménez Pearson MA, Galas M, Corso A, Hormazábal JC, Duarte Valderrama C, Salgado Marcano N, et
al. Consenso latinoamericano para definir, categorizar y notificar patógenos multirresistentes, con resistencia ex
tendida o panresistentes. Rev Panam Salud Pública [Internet]. 2019;1–8. Available from:
https://iris.paho.org/handle/10665.2/51470
Jabłońska-Trypuć A, Makuła M, Włodarczyk-Makuła M, Wołejko E, Wydro U, Serra-Majem L, et al. Inanimate
Surfaces as a Source of Hospital Infections Caused by Fungi, Bacteria and Viruses with Particular Emphasis on
SARS-CoV-2. Int J Environ Res Public Health [Internet]. 2022;19(13). Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265696/
Feng T, James A, Doumlele K, White S, Twardzik W, Zahid K, et al. Procalcitonin Levels in COVID-19 Pa
tients Are Strongly Associated with Mortality and ICU Acceptance in an Underserved , Inner City Population.
;(March 2020):1–11. Available from:
https://www. ncbi.nlm.nih.gov/pmc/articles/PMC8539303/#:~:text=- Conclusions%3A Procalcitonin showed the greatest,severity during COVID-19 infection.
Rivera-Fernandez R, Yáguez-Mateos L, Guerrero-Marin M, Pérez-Manrique RM, Rojas-Amezcua M, Pontes-Moreno AJ, et al. Evaluation of procalcitonin elevation during ICU stay and its relationship with mortality in ICU patients for COVID-19 with respiratory involvement. A multicenter prospective cohort study. Front Med [Internet]. 2022;9(December):1–14. Available from:
https://www.frontiersin.org/articles/10.3389/fmed.2022.972659/full
Nandi A, Pecetta S, Bloom DE. Global antibiotic use during the COVID-19 pandemic: analysis of pharmaceu-
tical sales data from 71 countries, 2020–2022. eClinical Medicine [Internet]. 2023;57:101848. DOI: https://doi.or-
g/10.1016/j.eclinm.2023.101848. Available from:
https://www.thelancet.com/journals/eclinm/article/PIIS25895370(23)00025-1/fulltext
Dueñas-Castell C, Polanco-Guerra CJ, Martinez-Ávila MC, Almanza Hurtado AJ, Rodriguez Yanez T, Gutie-
rrez-Ariza JC, et al. When to Use Antibiotics in COVID-19: A Proposal Based on Questions. Cureus [Internet].
;14(7):1–9. Available from:
https://assets.cureus.com/uploads/review_article/pdf/106827/20220827-24749-1xs1eel.pdf
Tiri B, Sensi E, Marsiliani V, Cantarini M, Priante G, Vernelli C, et al. Antimicrobial stewardship program, COVID-19, and infection control: Spread of carbapenem-resistant Klebsiella pneumoniae colonization in ICU COVID-19 patients. What did not work? J Clin Med [Internet]. 2020;9(9):1–9. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563368/
Stefanini I, De Renzi G, Foddai E, Cordani E, Mognetti B. Profile of bacterial infections in covid-19 patients: Antimicrobial resistance in the time of SARS-CoV-2. Biology (Basel) [Internet]. 2021;10(9). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467430/
Beatriz PA, Alberto MJ, Enrique MN, Guillermo RJ. El sexo como factor de riesgo de la mortalidad por COVID-19. Caso Ecuador Sex as a risk factor for COVID-19 mortality . Ecuador case. Portal Rev Científicas y Humanísticas
la Univ del Zulia, Venez [Internet]. 2021;49(2):1–10. Available from: https://produccioncientificaluz.org/index.php/kasmera/article/view/35672/39277
Casas-Rojo JM, Antón-Santos JM, Millán-Núñez-Cortés J, Lumbreras-Bermejo C, Ramos-Rincón JM, Roy-Vallejo
E, et al. Clinical characteristics of patients hospitalized with COVID-19 in Spain: Results from the SEMI-COVID-19
Registry. Rev Clin Esp [Internet]. 2020 Nov 1;220(8):480–94. Available from: https://www.sciencedirect.com/science/article/pii/S001425652030206X?via%3Dihub
Fabião J, Sassi B, Pedrollo EF, Gerchman F, Kramer CK, Leitão CB, et al. Why do men have worse COVID-19-re-
lated outcomes ? A systematic review and meta-analysis with sex adjusted for age. Brazilian J Med Biol Res [In-
ternet]. 2022;1–8. Available from:
The authors who publish in this journal accept the following conditions:
1. The authors retain the copyright and grant to the CAMbios MEDICAL-SCIENTIFIC JOURNAL HECAM the right of the first publication, with the work registered with the Creative Commons attribution license, which allows third parties to use the published material provided that they mention the authorship of the work and the first publication in this journal.
2. Authors can make other independent and additional contractual agreements for the non-exclusive distribution of the version of the article published in this journal (for example, include it in an institutional repository or publish it in a book) as long as it clearly indicates that the work was published. for the first time in the CAMbios MEDICAL-SCIENTIFIC JOURNAL HECAM.